Updates from PROT, MNTA, and LIFE
Updates from PROT, MNTA, and LIFE
crwefinancelogo2
signup3m
Proteonomix Inc (OTC BB: PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, recently reported it’s financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of .0 million, compared with a net loss of .8 million for the same period last year. At June 30, 2010, the Company had cash, cash equivalents, and marketable securities of .7 million, compared with .7 million at December 31, 2009.
Revenue for the second quarter of 2010 was .8 million, compared to .6 million for the same period last year. The decrease in revenue was due to a decrease in reimbursable manufacturing expenses associated with our M356 program and a decrease in reimbursable expenses associated with our enoxaparin sodium injection program as the ANDA review process approached completion.
Research and development expenses for the second quarter of 2010 were .8 million, compared to .7 million for the same period last year. The decrease in research and development expenses principally resulted from a decrease in manufacturing, process development and third-party research costs in support of our M356 program and clinical development costs due to the completion of our M118 Phase 2a clinical trial in June 2009.
MNTA is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. LIFE systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of .3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference.
LIFE reported their results for its second quarter ending June 30, 2010. Their Non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
Categories: 2010 Discoveris Of Biotechnology Tags: aging skin care, aging skin care products, anti aging skin care, bank, biotechnology company, cardiac injury, Care, Cell, cellular therapy, com, completion, cord blood bank, cord blood stem cells, crwefinancelogo, From, Future, human cells, June, Life, life updates, manufacturing, medicine institute, MNTA, momenta pharmaceuticals inc, nasdaq:mnta, number, OTC, otc bb, percent, platform, promising research, PROT, regenerative, skin, skin care products, Sperm, stem cell biology, Stock, Technology, therapeutic modalities, tissue bank, Translational, translational medicine, treatment, Updates, working, year, York
Recent reports for PROT, LIFE, and MNTA
Recent reports for PROT, LIFE, and MNTA
crwefinancelogo2
signup3m
Proteonomix Inc (OTC:PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. LIFE systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of .3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference.
LIFE reported their results for its second quarter ending June 30, 2010. Their Non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, recently reported it’s financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of .0 million, compared with a net loss of .8 million for the same period last year. At June 30, 2010, the Company had cash, cash equivalents, and marketable securities of .7 million, compared with .7 million at December 31, 2009. Revenue for the second quarter of 2010 was .8 million, compared to .6 million for the same period last year. The decrease in revenue was due to a decrease in reimbursable manufacturing expenses associated with our M356 program and a decrease in reimbursable expenses associated with our enoxaparin sodium injection program as the ANDA review process approached completion. Research and development expenses for the second quarter of 2010 were .8 million, compared to .7 million for the same period last year. The decrease in research and development expenses principally resulted from a decrease in manufacturing, process development and third-party research costs in support of our M356 program and clinical development costs due to the completion of our M118 Phase 2a clinical trial in June 2009.
MNTA is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
The E2O Global Team presents Evolvs Compensation plan and how to get started as an Evolv Member. (info@e2oglobal.com) Team E2O Global is exploding throughout the US and Canada every day. We have seasoned business builders and professional trainers to help you get started quickly and to set you on a path to building a huge Evolv business. Evolv was created by the late Gene Kaiser of Houston, Texas and went to market in October 2009. America is already talking about it. Gene Kaiser made his first mark in the scientific community in the 1950s with his invention of Thin Set Mortar. Any home with tile or stone floors probably contains Genes invention. Gene Kaiser was a World War II hero and the last known survivor of the USS Orca that was exposed to massive amounts of radiation during the Atomic Bomb testing off Bikini Island in the 1940s. Gene also suffered from lifelong heart problems and finally developed bone marrow cancer in his mid to late 70s. Once, discovered, the doctors gave Gene less than 6 months to live. Amazingly, Gene survived another four years to age 82 and it was not the bone marrow cancer that took his life. Gene believed he survived and felt good in his later years because he was drinking the formula that today has become known as Archaea Active TM. Gene and two fellow scientists Dr. Jay and Dr. Jock Collins worked on the all natural formula for many years. Gene began mixing Archaea Active TM with water and drinking it in 2000. Gene would often say to his …
Categories: 2010 Discoveris Of Biotechnology Tags: aging skin care, aging skin care products, anti aging skin care, bank, biotechnology company, cardiac injury, Care, Cell, cellular therapy, com, completion, cord blood bank, cord blood stem cells, crwefinancelogo, Future, global biotechnology, human cells, June, Life, manufacturing, medicine institute, MNTA, nasdaq:mnta, number, OTC, percent, platform, promising research, PROT, Recent, regenerative, Reports, scientific exploration, skin, skin care products, Sperm, sperm bank, stem cell biology, Stock, Technology, therapeutic modalities, tissue bank, tools company, Translational, translational medicine, treatment, working, year, York
Important Projects in the World
Important Projects in the World
At any given moment, millions of scientists, researchers, programmers and others, are working for the common good. Some have selfish motivations, and others may not understand the import of their work but in the end we may all benefit from their endeavors. Since we do not know what the future holds, it is difficult to accurately predict which projects will turn out to be the most significant; it is likely that many ventures will end in failure, and in retrospect, we may even be surprised that some were even undertaken. We can, however, uncover some leading candidates for most critical projects currently underway.
Medicine – We’ll start with the most obvious. Medical improvements can benefit all of us, either directly or indirectly. Cures to epidemics, or new medical therapies, perhaps genetic, can improve the quality of our lives. A cure for cancer or AIDS can end up saving millions of human lives and elevating the quality of life for millions more. Perhaps the most important work in this area is being performed by those trying to come up with new and faster methods to cure communicable diseases; there are many teams preemptively working on systems and techniques to quickly determine the root causes of new diseases and to devise the plans to eradicate them.
Diplomacy – The population of our planet has been steadily increasing, but living space and available natural resources remain finite. Tensions are likely to flare, and there are many people working to make sure that the various power structures in the world will function cohesively in the future. Major discord between competing entities can lead to unprecedented harm. Those that are working to eradicate terrorism at its source, and those that work toward international accord may be involved in today’s most important work.
Spiritual - There are many people that dismiss the importance of physical practicalities of our lives, and focus their efforts on more grandiose ends such as personal fulfillment, enlightenment and moral living. They urge us to strive for meaningful lives as opposed to merely comfortable ones; others try to shift attention to the afterlife as opposed to the here and now. It is possible that the work done in promoting these spiritual ends will accomplish the most for humanity in the long run.
Alternative Energy – Just a few hundred years ago, the issue of energy was mostly irrelevant. People collected wood for cooking and heat, and maybe used sunlight to warm water. Modern society, however, is entirely different, and much of what we do is directly or indirectly based on energy. Energy is used for transportation, industrial production, communications – even the harvesting and transportation of fruits and vegetables relies on a surprising amount of energy.
Nanotechnology – Nanotechnology is a field of applied science and technology covering a broad range of topics. The main unifying theme is the control of matter on a scale smaller than one micrometre, as well as the fabrication of devices on this same length scale. It is a highly multidisciplinary field, drawing from fields such as colloidal science, device physics, and supramolecular chemistry. Much speculation exists as to what new science and technology might result from these lines of research. Some view nanotechnology as a marketing term that describes pre-existing lines of research.
Computing, Internet and Artificial Intelligence – As processing power improves, the functionality and value of computers tends to increase significantly. The best computers of just a decade ago could not even handle tasks that the average desktop computer now handles with ease. The networking of these computers has expanded the possibilities even further. Computing and the internet has already changed many of our lives. We plan trips, research products, and explore our history in entirely new and more efficient ways. It seems clear, however, that the impact of the internet has just begun its influence on our lives.
Robotics – The field of robotics has been around for many years, and although there have been plenty of advancements, robots do not seem to affect our daily lives in any significant way. Of course robots make great toys, many are used in manufacturing facilities, and others are used for sea exploration or bomb detonation. It is likely, however, that all of this will change. As computing power improves and becomes less expensive, robots are given the ‘brains’ that they need to become very useful.
Space Travel – To some, this may be the most perplexing entry on this list. Suppose that the medical researchers described above are not able to stave off some future viral plague. Or imagine the nightmare scenario of a huge asteroid colliding with earth. What if drastic climate change ends up rendering our planet inhospitable to any form of life.
It is clear that some important issues were omitted from the list above, but it was not intended to be exhaustive. It may turn out that the most important work isn’t even on the radar right now. What is clear, is that although we are faced with unprecedented issues and problems, we have the technology and capacity to solve them; it is certainly a very exciting time to be alive!
Find more about Important Projects at www.ShoppingSoLow.com
Find more information about India College at www.FindCollegesIndia.com
Video by Hewlett-Packard introducing Nanotechnology. So when someone like me says they’re studying nanotechnology at Uni you know what it is.
Video Rating: 4 / 5
Categories: Nanotechnology Venture Tags: "hewlett packard" computer, amount, colloidal, communicable diseases, control, critical projects, cure, cure for cancer, Diplomacy, discord, endeavors, enlightenment, entities, flare, fulfillment, Future, Good, heat, import, Important, Improvements, international accord, living space, medical therapies, micrometre, moment millions, motivations, Nanotechnology, natural resources, PLANET, power, power structures, Production, programmers, projects, quality of life, retrospect, root, Science, sunlight, Technology, tensions, terrorism, transportation, Wood, work, World
